TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18060379

Group type: EXPERIMENTAL
Intervention: Trigeminocardiac reflex (TCR) occurrence during surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TCR occurrence during nasal mucosa preparation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels after TCR occurrence
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation of tumor necrosis factor A and noradrenalin levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atropine administration
Number of subjects: 40
Study: 16469681

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily for 14 days
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 12971705

Group type: EXPERIMENTAL
Intervention: Additional early physiotherapy (AEP) for 45 minutes, five days a week for four weeks starting within the first week since stroke onset
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine therapy (RT) group received no professional rehabilitation therapy
Number of subjects: 156
Study: 11033383

Group type: EXPERIMENTAL
Intervention: Dose-response studies in Phase I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-response studies in Phase II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-response assessment
Number of subjects: 0
Study: 9436670

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (Ig) administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Number of subjects: 46
Study: 8292687

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine hydrochloride (2 micrograms/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with DSM‐III‐R panic disorder
Number of subjects: 60
Study: 3538478

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with conical spacer device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metered dose inhaler without conical spacer device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebuliser treatment
Number of subjects: 0
Study: 31408652

Group type: EXPERIMENTAL
Intervention: Anterior approach POEM
Number of subjects: 150

Group type: COMPARATOR
Intervention: Posterior approach POEM
Number of subjects: 150
Study: 31487231

Group type: EXPERIMENTAL
Intervention: High-tech visual scene displays (VSDs)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low-tech isolated picture symbols
Number of subjects: 3
Study: 27477525

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27493757

Group type: EXPERIMENTAL
Intervention: Group medical appointments (GMA's; novel intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Individual medical appointments (IMA's; care-as-usual; control)
Number of subjects: 100
Study: 24213952

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN) starting on day 8
Number of subjects: 4640

Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 4640
Study: 22980698

Group type: EXPERIMENTAL
Intervention: Combined exercise program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 100

Group type: COMPARATOR
Intervention: No exercise program (Control)
Number of subjects: 100
Study: 19756527

Group type: COMPARATOR
Intervention: Escitalopram (10 mg)
Number of subjects: 20
Study: 17320568

Group type: EXPERIMENTAL
Intervention: 20% mannitol 0.5 g/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline 2.5 mL/kg
Number of subjects: 50
Study: 14634492

Group type: EXPERIMENTAL
Intervention: Polyenylphosphatidylcholine (PPC)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: PPC
Number of subjects: 789
Study: 11007673

Group type: EXPERIMENTAL
Intervention: Supine position (Baseline)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Supine position (Diuretic)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Upright position (Baseline)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Upright position (Diuretic)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Supine position (Weight change)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Upright position (Weight change)
Number of subjects: 7
Study: 8832319

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 1794

Group type: COMPARATOR
Intervention: DHS nail
Number of subjects: 1794
Study: 1471489

Group type: EXPERIMENTAL
Intervention: Fornix-based flap procedure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Limbus-based flap procedure
Number of subjects: 18
Study: 6378422

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional treatment (nitrates and beta-blockers)
Number of subjects: 138
Study: 3511709

Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg three times daily by mouth for 7 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 58
Study: 29281797

Group type: EXPERIMENTAL
Intervention: Three 3.5-mm knotless screw-in anchors
Number of subjects: 36

Group type: COMPARATOR
Intervention: Four-anchor hybrid construct (two 3.0-mm knotted push-in anchors and two 2.9-mm knotless push-in anchors)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Three 3.0-mm knotless push-in anchors
Number of subjects: 36
Study: 28579744

Group type: EXPERIMENTAL
Intervention: TearLab Osmolarity System
Number of subjects: 20

Group type: COMPARATOR
Intervention: i-Med i-Pen
Number of subjects: 20
Study: 29144074

Group type: EXPERIMENTAL
Intervention: Early NASG application at clinic level
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard management for OH at clinic level, NASG applied at RH (Control)
Number of subjects: 0
Study: 23615499

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PLEX)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (IV MeP)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Primary composite outcome (death or ESRD)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: ESRD
Number of subjects: 137
Study: 21322282

Group type: EXPERIMENTAL
Intervention: Ganciclovir (induction and maintenance treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 76
Study: 18400708

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Furanocoumarin-free grapefruit juice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Orange juice (control)
Number of subjects: 18
Study: 16596926

Group type: EXPERIMENTAL
Intervention: Nelson‐Moberg Expanded CONSORT Instrument (NMECI)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interrater reliability of NMECI
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Kappa statistics for individual sub‐items
Number of subjects: 14
Study: 12686276

Group type: EXPERIMENTAL
Intervention: Auditory processing training software for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal‐learning and learning‐impaired children who did not participate in any remedial programs)
Number of subjects: 0
Study: 10880804

Group type: COMPARATOR
Intervention: Control EEG from 26 healthy subjects
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Interictal EEG from 25 patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ictal EEG from 25 patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control EEG from 26 healthy subjects and patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: EEG correlation dimension
Number of subjects: 51
Study: 9200528

Group type: EXPERIMENTAL
Intervention: Paroxetine doses ranged from 10 to 40 mg/day
Number of subjects: 18
Study: 1555692

Group type: EXPERIMENTAL
Intervention: Long protocol (subcutaneous buserelin acetate 200 micrograms/d from day 1, hMG started after 14 days)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Short protocol (subcutaneous buserelin acetate 200 micrograms/d from day 2, hMG from day 3)
Number of subjects: 91
Study: 3904102

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPN) 375 mg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoclopramide (MCP) 1 mg/kg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Number of subjects: 60
Study: 30881606

Group type: EXPERIMENTAL
Intervention: Self-management plus physiotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 8
Study: 30107488

Group type: EXPERIMENTAL
Intervention: 120 g full-fat Irish cheddar cheese (FFCC)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Butter (49 g), calcium caseinate powder (30 g), and Ca supplement (CaCO3) (500 mg) (BCC)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 120 g reduced-fat Irish cheddar cheese + butter (21 g) (RFC + B)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 120 g FFCC (as per A) after a 6-wk run-in period
Number of subjects: 164
Study: 27496255

Group type: EXPERIMENTAL
Intervention: Employment-focused case management (CMRE)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: CMRE
Number of subjects: 320

Group type: COMPARATOR
Intervention: SC
Number of subjects: 320
Study: 25481088

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone administration once per week for 8 weeks starting 2 weeks prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo intramuscularly instead of testosterone
Number of subjects: 0
Study: 22440853

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus casei Shirota) - 2 bottles of fermented milk containing ≥ 6.5 × 10(9) live LcS/bottle for 176 days
Number of subjects: 737

Group type: COMPARATOR
Intervention: Placebo (similar drink with no bacteria)
Number of subjects: 737
Study: 20392360

Group type: EXPERIMENTAL
Intervention: Home non-invasive ventilation (NIV)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) 5 cm H(2)O
Number of subjects: 47
Study: 18511650

Group type: EXPERIMENTAL
Intervention: Abetimus sodium 600 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Abetimus sodium 1200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Abetimus sodium 2400 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All doses of abetimus sodium
Number of subjects: 24
Study: 16425357

Group type: EXPERIMENTAL
Intervention: He Jie Tang (HJT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Combined medication (Control group)
Number of subjects: 85
Study: 12874182

Group type: EXPERIMENTAL
Intervention: Lotrafiban 30 or 50 mg BID
Number of subjects: 9190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9190

Group type: EXPERIMENTAL
Intervention: Aspirin >162 mg/d
Number of subjects: 9190
Study: 10808042

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg SQ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8657986

Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Valerian and hops tablets
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Valerian syrup
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1515258

Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Droloxifene (all doses)
Number of subjects: 369
Study: 6394143

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Caffeine (100 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid + Caffeine (200 mg + 100 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid + Metoclopramide (200 mg + 10 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31032783

Group type: COMPARATOR
Intervention: Topical minoxidil 5% lotion applied twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mesotherapy injected once weekly
Number of subjects: 30
Study: 29061185

Group type: EXPERIMENTAL
Intervention: Community Navigator intervention (n=30), up to ten sessions over 6 months.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care and written information about local community resources (Control group, n=10).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with participants, staff, and stakeholders.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Potential primary and secondary outcomes for future trial.
Number of subjects: 40
Study: 25421606

Group type: EXPERIMENTAL
Intervention: Competitive Memory Training (COMET)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study: 24657006

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (module theme: people-themed)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (module theme: thoughts-themed)
Number of subjects: 176
Study: 21851027

Group type: EXPERIMENTAL
Intervention: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) with adrenaline (2 mcg/ml) (ABF group)
Number of subjects: 164

Group type: COMPARATOR
Intervention: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) without adrenaline (BF group)
Number of subjects: 164
Study: 19138601

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF) 400 mg/24 hours for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxicillin and clavulanic acid (AMX-CLV) 500/125 mg/8 hours for 5 days
Number of subjects: 100
Study: 17366288

Group type: EXPERIMENTAL
Intervention: ABLE patients
Number of subjects: 699

Group type: COMPARATOR
Intervention: Non-ABLE patients
Number of subjects: 699
Study: 15450280

Group type: EXPERIMENTAL
Intervention: CRT+AF Suppression (algorithm ON)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CRT only (algorithm OFF)
Number of subjects: 0
Study: 11230488

Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (IFNalpha2b)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combination of high-dose interferon alfa-2b (IFNalpha2b) and GMK
Number of subjects: 107
Study: 9021810

Group type: EXPERIMENTAL
Intervention: Pulsed regimen of 6-mercaptopurine and methotrexate
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Three-drug regimen during induction therapy
Number of subjects: 811

Group type: COMPARATOR
Intervention: Regimen with cranial irradiation
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Risk group-directed protocol 911
Number of subjects: 811

Group type: COMPARATOR
Intervention: Protocol 811
Number of subjects: 811

Group type: COMPARATOR
Intervention: Protocol 841
Number of subjects: 811

Group type: COMPARATOR
Intervention: Protocol 874
Number of subjects: 811
Study: 7950332

Group type: EXPERIMENTAL
Intervention: Norfloxacin (0.3% solution, 50 ul)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ofloxacin (same dose as norfloxacin)
Number of subjects: 30
Study: 3296435

Group type: EXPERIMENTAL
Intervention: Combination of radiation and hormonotherapy (17-hydroxyprogesterone caproate)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not receiving hormonotherapy)
Number of subjects: 76
Study: 29500811

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Propranolol + Pyridostigmine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Bisoprolol + Pyridostigmine
Number of subjects: 77
Study: 28738794

Group type: COMPARATOR
Intervention: Telephone-assisted self-help for parents and teachers
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy combined with psychoeducation
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 521
Study: 26518158

Group type: EXPERIMENTAL
Intervention: Xyloglucan
Number of subjects: 150

Group type: COMPARATOR
Intervention: Diosmectite
Number of subjects: 150

Group type: COMPARATOR
Intervention: S. bouliardii
Number of subjects: 150
Study: 23453611

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone as submucosal injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: No steroid administration (control group)
Number of subjects: 100
Study: 22533150

Group type: EXPERIMENTAL
Intervention: Cinacalcet (Mimpara) accompanied by alfacalcidol (0.25 to 0.5 microg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cinacalcet (Mimpara) accompanied by alfacalcidol
Number of subjects: 82
Study: 19117731

Group type: EXPERIMENTAL
Intervention: Teicoplanin (10mg/kg single dose upon introduction of anaesthesia)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Comparator (multiple doses of broad-spectrum antimicrobials for 4-6 days)
Number of subjects: 616
Study: 17381494

Group type: EXPERIMENTAL
Intervention: Lipid-heparin emulsion (LHE) infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal saline (NaCl 0.9%) infusion (control)
Number of subjects: 7
Study: 15018884

Group type: EXPERIMENTAL
Intervention: Cheek swab method (Group 1)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Cheek swab method (Group 2)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Mouthwash swish method (Group 3)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Mouthwash swish method (Group 4)
Number of subjects: 656
Study: 11394552

Group type: EXPERIMENTAL
Intervention: Major and minor stress assessment using Life Experiences Survey and Weekly Stress Inventory
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: RAND 36‐Item Health Survey
Number of subjects: 183
Study: 9932220

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (amoxicillin‐clavulanic acid, 1.5 g/24 h for 10 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Small intestinal bacterial overgrowth syndrome (group 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No bacterial overgrowth (group 2)
Number of subjects: 35
Study: 8563533

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 456

Group type: COMPARATOR
Intervention: Mixed therapy (deep breathing exercises for low risk patients and incentive spirometry plus physiotherapy for high risk patients)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Physiotherapy for high risk patients
Number of subjects: 456
Study: 2370647

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 24
Study: 7007837

Group type: EXPERIMENTAL
Intervention: Trimipramine 25 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31852536

Group type: EXPERIMENTAL
Intervention: Tobacco cessation group behavioral intervention (5As: Ask, Advise, Assess, Assist, Arrange)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study: 28921781

Group type: EXPERIMENTAL
Intervention: VGCV for 200 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: VGCV for 100 days followed by 3 doses of monthly CMV HIG
Number of subjects: 40
Study: 25817172

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: Focal/grid laser treatment
Number of subjects: 70
Study: 24557418

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine-cisplatin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo plus capecitabine-cisplatin
Number of subjects: 202
Study: 23228527

Group type: EXPERIMENTAL
Intervention: Patient-directed music (PDM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Headphones only to block ICU noise
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual ICU care
Number of subjects: 65
Study: 21514986

Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EasyTube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: I-Gel
Number of subjects: 40
Study: 18289149

Group type: EXPERIMENTAL
Intervention: Continuous paroxetine treatment (20 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent paroxetine treatment (20 mg daily)
Number of subjects: 36
Study: 17044464

Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN) 20 mg bid for 5 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12670617

Group type: EXPERIMENTAL
Intervention: Tinnitus Coping Training (TCT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Minimal-contact education (MC-E)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Minimal-contact relaxation (MC-R)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting-list control (WC)
Number of subjects: 43
Study: 11057781

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Purified mineral talc
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Autologous blood
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aspiration only
Number of subjects: 56
Study: 9564197

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28